MATHIAS, John Paul,DENNY, Rajiah Aldrin,EFREMOV, Ivan Viktorovich,GAVRIN, Lori Krim,STROHBACH, Joseph Walter,THRORARENSEN, Atli,ZAPF, Christoph Wolfgang,LIMBURG, David Christopher,ELBAUM, Daniel
申请号：
CR20190292
公开号：
CR20190292A
申请日:
2017.11.17
申请国别(地区):
CR
年份:
2019
代理人:
摘要：
The invention refers to formula one compounds, wherein R1a, r1b, R2, R3, R4, W, y and Z are as described in this document and refer to the pharmaceutically acceptable salts. These compounds are enhancers of chemical fiber outer membrane conduction regulators (CFTR). The invention also discloses pharmaceutical ingredients containing optional compounds, their use in combination with other therapeutic agents, and methods of enhancing capabilities in mammals (including humans) through the use of these compounds. These compounds contribute to the treatment of chemical fibers (CF),Asthma, bronchopathy, COPDConstipation, diabetes, xerofalmia, pancreatitis, adrenaline, sogren's syndrome and other CFTR related diseases: current inventions related to formula compounds (I),Wherein R1 A，R1 B，R2，R3，R4，W，Y，and Z are described here，and pharmaceutically acceptable salts there. The complexes are potentials of cyclic fibrosis transmembrane production regulator (CFTR) The invention also discloses pharmaceutical compositions compositing the compound，optional in combination with additional therapeutic agents，and methods of potentiating，in mammals，including humans，cftr by administration of the compounds. These compounds are used to treat cyclofibrosis (CF),ASMA, bronchitis, COPDConservation, diabetes mellitus, dry eye disease, pancreatis, rhinositis, Sjogren's syndrome, and other CFTR associated disordersLa presente invención se refiere a compuestos de la Fórmula I, en donde R1a, R1b, R2, R3, R4, W, Y y Z son como se describen en este documento, y a sales farmacéuticamente aceptable de los mismos. Los compuestos son potenciadores del regulador de conductancia transmembranal de la fibrosis quística (CFTR). La invención también da a conocer composiciones farmacéuticas que comprenden el compuesto opcionalmente en combinación con agentes terapéuticos adicionales, y métodos de potenciación, en mamíferos incluyendo humanos, de CFTR por la administración de los compuestos. Estos compuestos son
